WO2004044589A3 - Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 3 (edg3) - Google Patents

Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 3 (edg3) Download PDF

Info

Publication number
WO2004044589A3
WO2004044589A3 PCT/EP2003/012120 EP0312120W WO2004044589A3 WO 2004044589 A3 WO2004044589 A3 WO 2004044589A3 EP 0312120 W EP0312120 W EP 0312120W WO 2004044589 A3 WO2004044589 A3 WO 2004044589A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
edg3
sphingolipid
therapeutics
diagnostics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/012120
Other languages
French (fr)
Other versions
WO2004044589A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to EP03779825A priority Critical patent/EP1597582A2/en
Priority to AU2003287976A priority patent/AU2003287976A1/en
Publication of WO2004044589A2 publication Critical patent/WO2004044589A2/en
Publication of WO2004044589A3 publication Critical patent/WO2004044589A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a human EDG3 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, urology diseases, cancer diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, urology diseases, cancer diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of EDG3 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2003/012120 2002-11-13 2003-10-31 Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 3 (edg3) Ceased WO2004044589A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP03779825A EP1597582A2 (en) 2002-11-13 2003-10-31 Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 3 (edg3)
AU2003287976A AU2003287976A1 (en) 2002-11-13 2003-10-31 Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 3 (edg3)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02025501 2002-11-13
EP02025501.4 2002-11-13

Publications (2)

Publication Number Publication Date
WO2004044589A2 WO2004044589A2 (en) 2004-05-27
WO2004044589A3 true WO2004044589A3 (en) 2004-06-17

Family

ID=32309334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/012120 Ceased WO2004044589A2 (en) 2002-11-13 2003-10-31 Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 3 (edg3)

Country Status (3)

Country Link
EP (1) EP1597582A2 (en)
AU (1) AU2003287976A1 (en)
WO (1) WO2004044589A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120071448A1 (en) * 2009-05-05 2012-03-22 Allergan, Inc. S1P3 Receptor Inhibitors for Treating Conditions of the Eye

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130067A (en) * 1998-05-20 2000-10-10 Smithkline Beecham Corporation Human EDG3sb gene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130067A (en) * 1998-05-20 2000-10-10 Smithkline Beecham Corporation Human EDG3sb gene

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 20 May 2001 (2001-05-20), Database accession no. AR112475 *
MAZURAI D. ET AL: "Cell type-specific localization of human cardiac S1P receptors", JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, vol. 50, no. 5, May 2002 (2002-05-01), pages 661 - 669, XP009029256 *
PYNE S ET AL: "REVIEW ARTICLE SPHINGOSINE 1-PHOSPHATE SIGNALLING IN MAMMALIAN CELLS", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, GB, vol. 349, 2000, pages 385 - 402, XP000939036, ISSN: 0264-6021 *
RACKE K ET AL: "Potential role of EDG receptors and lysophospholipids as their endogenous ligands in the respiratory tract", PULMONARY PHARMACOLOGY AND THERAPEUTICS, vol. 13, no. 3, 2000, &, pages 99 - 114, XP002277298, ISSN: 1094-5539 *
ZHANG G ET AL: "Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 227, no. 1, 4 February 1999 (1999-02-04), pages 89 - 99, XP004155772, ISSN: 0378-1119 *

Also Published As

Publication number Publication date
AU2003287976A1 (en) 2004-06-03
EP1597582A2 (en) 2005-11-23
WO2004044589A2 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
WO2004042389A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
WO2004008153A3 (en) Diagnostics and therapeutics for diseases associated with homo sapiens putative neurotransmitter receptor (pnr)
WO2003093816A3 (en) Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2004080373A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
WO2004042402A3 (en) Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2004044589A3 (en) Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 3 (edg3)
WO2003095967A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
WO2004071378A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
WO2003065044A3 (en) Diagnostics and therapeutics for diseases associated with gpr72
WO2004038421A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
WO2003096020A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
WO2004057328A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor 38 (gpr38)
WO2004048978A3 (en) Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37)
WO2004038407A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
WO2004044587A3 (en) Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 5 (edg5)
WO2003100433A3 (en) Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (avpr3)
WO2004015422A3 (en) Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1)
WO2005040790A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2003072122A3 (en) Diagnostics and therapeutics for diseases associated with endothelial differentiation lysophosphatic acid g-protein-coupled receptor 7 (edg7)
WO2003080098A3 (en) Diagnostics and therapeutics for diseases associated with homo sapiens formyl peptide receptor-like 2
WO2004015427A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003779825

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003779825

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP